127 related articles for article (PubMed ID: 3114198)
1. Characteristics of mouse thymocyte-derived, interleukin 2-activated killer cells and their precursors.
Yagi H; Nishimura T; Hashimoto Y
Jpn J Cancer Res; 1987 Jul; 78(7):721-8. PubMed ID: 3114198
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer (LAK) cells. III. Characterization of LAK precursors and susceptible target cells within the murine thymus.
Ballas ZK; Rasmussen W
J Immunol; 1987 Nov; 139(10):3542-9. PubMed ID: 3500221
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
4. Generation of lymphokine-activated killer cell activity from human thymocytes.
Ramsdell FJ; Golub SH
J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246
[TBL] [Abstract][Full Text] [Related]
5. The precursor cells of mouse lymphokine-activated killer (LAK) cells.
Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
Thymus; 1987; 9(3):131-9. PubMed ID: 3495912
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
Yun YS; Hargrove ME; Ting CC
J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
[TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
10. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations.
Ballas ZK; Rasmussen W; van Otegham JK
J Immunol; 1987 Mar; 138(5):1647-52. PubMed ID: 2879870
[TBL] [Abstract][Full Text] [Related]
12. Properties of target molecule of murine lymphokine-activated killer (LAK) cells and the clones.
Hashimoto Y; Kato K; Sato N; Yagi H; Yagita H; Nishimura T
Princess Takamatsu Symp; 1988; 19():315-22. PubMed ID: 3077625
[TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma is produced by activated immature mouse thymocytes and inhibits the interleukin 4-induced proliferation of immature thymocytes.
Ransom J; Fischer M; Mosmann T; Yokota T; DeLuca D; Schumacher J; Zlotnik A
J Immunol; 1987 Dec; 139(12):4102-8. PubMed ID: 3121729
[TBL] [Abstract][Full Text] [Related]
14. Cultured Lyt-2- L3T4- T lymphocytes from normal thymus or lpr mice express a broad spectrum of cytolytic activity.
Budd RC; Cerottini JC; MacDonald HR
J Immunol; 1986 Dec; 137(12):3734-41. PubMed ID: 3491147
[TBL] [Abstract][Full Text] [Related]
15. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
16. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
Ohnishi H; Lin KM; Chu TM
Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
[TBL] [Abstract][Full Text] [Related]
17. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
Ting CC; Hargrove ME; Yun YS
J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
[TBL] [Abstract][Full Text] [Related]
18. Anti-Thy-1 plus complement-treated, cultured bone marrow cells resemble fetal thymocytes in killer cell function and marker expression.
Hurwitz JL; McAndrew EC; Doherty PC
J Immunol; 1986 Sep; 137(6):1757-63. PubMed ID: 2875109
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of cytotoxic granules from human lymphokine (interleukin 2) activated killer cells.
Lowrey DM; Hameed A; Lichtenheld M; Podack ER
Cancer Res; 1988 Aug; 48(16):4681-8. PubMed ID: 3260817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
